Drug profile · INN
procainamide hydrochloride
PRONESTYL
procainamide hydrochloride (PRONESTYL) is a sodium channel alpha subunit blocker. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Drug details — procainamide hydrochloride
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
procainamide hydrochloride (PRONESTYL) is a sodium channel alpha subunit blocker. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is procainamide hydrochloride?
procainamide hydrochloride (PRONESTYL) is a sodium channel alpha subunit blocker. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for procainamide hydrochloride?
PRONESTYL is a marketed brand name for procainamide hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of procainamide hydrochloride?
procainamide hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.